Novartis says Alcon glaucoma treatment approved in EU

ZURICH Mon Jul 28, 2014 5:50am EDT

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel October 22, 2013.   REUTERS/Arnd Wiegmann

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel October 22, 2013.

Credit: Reuters/Arnd Wiegmann

Related Topics

ZURICH (Reuters) - Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease.

Alcon said in a statement on Monday the Simbrinza eye drops suspension had been approved to decrease elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.

"We are pleased to introduce the only fixed combination therapy without a beta-blocker to help more glaucoma patients manage their progressive eye condition," Jeff George, global head of Alcon, said in the statement.

(Reporting by Silke Koltrowitz; Editing by Kenneth Maxwell)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.